임상가를 위한 특집 2 - Bisphosphonate-related osteonecrosis of the jaw(BRONJ)에 대한 biochemical bone markers와 악골괴사와 연관된 nonbisphosphonate drugs |
이덕원1, 이현우2, 권용대3 |
1경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터 2경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터 3경희대학교 치의학전문대학원 구강악안면외과학교실, 난치성턱뼈질환센터 |
Biochemical bone markers of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and nonbisphosphonate drugs in osteonecrosis of the jaw |
Deok-Won Lee1, Hyun-Woo Lee2, Yong-Dae Kwon3 |
1Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University 2Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University 3Department of Oral and Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University |
|
Abstract |
Bisphosphonates are widely used in the treatment of many medical conditions, such as osteoporosis, multiple myeloma, Paget's disease, etc. However, side effect has been documented in the published data during the past years, osteonecrosis of the jaw in patients receiving long-term bisphosphonate therapy. Although pathogenesis of BRONJ(bisphophonate-related osteonecrosis of the jaw) is not yet fully understood, it is currently known to be a disease associated with suppressed bone turnover by bisphopbonate. Recent literature has indicated a similar association with nonbisphosphonate drugs used in cancer therapy including monoclonal antibodies denosumab and bevacizumab and multikinase inhibitor sunitinib. Accordingly, many studies have been carried out on the biochemical markers examination to assess the risk for BRONJ. The treatment of BRONI is reported with a review of the relevant literature. However, there is still a controversial discussion about the adequate treatment. It is necessary to accumulate further studies in order to establish more useful biochemical markers and effective treatment for BRONJ. |
Key Words:
Bisphosphonale-related osteonecrosis of the jaw(BRONJ);Biochemical bone marker;nonbisphosphonate drugs; |
|